A detailed history of Raymond James & Associates transactions in Veru Inc. stock. As of the latest transaction made, Raymond James & Associates holds 33,079 shares of VERU stock, worth $23,486. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,079
Previous 26,961 22.69%
Holding current value
$23,486
Previous $22,000 13.64%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$0.77 - $1.04 $4,710 - $6,362
6,118 Added 22.69%
33,079 $25,000
Q2 2024

Jul 19, 2024

BUY
$0.76 - $1.79 $20,490 - $48,260
26,961 New
26,961 $22,000
Q2 2022

Aug 12, 2022

BUY
$4.35 - $15.85 $47 - $174
11 Added 0.01%
85,111 $962,000
Q1 2022

May 11, 2022

BUY
$4.55 - $6.41 $18,200 - $25,640
4,000 Added 4.93%
85,100 $411,000
Q4 2021

Feb 08, 2022

BUY
$5.89 - $9.73 $5,890 - $9,730
1,000 Added 1.25%
81,100 $478,000
Q2 2021

Aug 11, 2021

SELL
$7.24 - $11.2 $88,523 - $136,942
-12,227 Reduced 13.24%
80,100 $646,000
Q1 2021

May 14, 2021

BUY
$8.05 - $20.78 $70,196 - $181,201
8,720 Added 10.43%
92,327 $995,000
Q4 2020

Feb 12, 2021

SELL
$2.36 - $9.99 $15,087 - $63,866
-6,393 Reduced 7.1%
83,607 $723,000
Q4 2019

Feb 12, 2020

SELL
$1.86 - $3.35 $139,500 - $251,250
-75,000 Reduced 45.45%
90,000 $302,000
Q2 2019

Aug 06, 2019

BUY
$1.26 - $2.14 $50,400 - $85,600
40,000 Added 32.0%
165,000 $351,000
Q1 2019

May 06, 2019

BUY
$1.2 - $1.59 $44,400 - $58,830
37,000 Added 42.05%
125,000 $183,000
Q4 2018

Feb 11, 2019

BUY
$1.21 - $1.54 $1,210 - $1,540
1,000 Added 1.15%
88,000 $123,000
Q3 2018

Nov 14, 2018

BUY
$1.38 - $2.27 $85,560 - $140,740
62,000 Added 248.0%
87,000 $124,000
Q2 2018

Aug 14, 2018

BUY
$1.64 - $2.29 $41,000 - $57,250
25,000 New
25,000 $51,000

Others Institutions Holding VERU

About VERU INC.


  • Ticker VERU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,146,704
  • Market Cap $56.9M
  • Description
  • Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N....
More about VERU
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.